摘要
目的 探究格列齐特和西格列汀对胰岛素治疗血糖控制欠佳肥胖2型糖尿病患者的效果。方法 选取本院2015年3月-2017年1月收治的80例胰岛素治疗血糖控制欠佳肥胖2型糖尿病患者,随机均分为2组,每组40例。对照组采用格列齐特治疗,观察组采用西格列汀治疗。观察比较2组患者治疗效果。结果 观察组餐后2小时血糖水平改善明显优于对照组,体质量、血压、空腹血糖等2组均有改善,且组间差异无统计学意义;观察组不良反应发生率为2.5%,对照组为10.0%,差异无统计学意义（P〈0.05）。结论 格列齐特和西格列汀对胰岛素治疗血糖控制欠佳肥胖2型糖尿病患者的疗效分析发现,西格列汀对于患者的血糖改善效果较高,同时减少不良反应发生,因此用药更加安全,值得临床推广应用。
Objective To explore the effect of gliclazide and Sig Leo Dean on insulin treatment for poor glycemic control in obese patients with type 2 diabetes mellitus. Methods 80 cases of insulin treatment for poor glycemic control in obese patients with type 2 diabetes mellitus treated in our hospital from March 2015 to January 2017 were randomly divided into two groups,with 40 cases in each group.The control group was treated with gliclazide The observation group was treated with Sig Leo Dean.The therapeutic effects of the two groups were observed and compared. Results 2 hours postprandial blood glucose levels improved in the observation group was better than that of the control group, the body weight, blood pressure, fasting blood glucose of two groups were improved, and there were no significant difference between the two groups; The incidence rate of adverse reactions was 2.5% in the observation group, 10% in the control group, the difference was not statistically significant （P〈0.05）. Conclusion Analysis of gliclazide and Sig Leo Dean on insulin treatment for poor glycemic control in obese patients with type 2 diabetes mellitus curative effect, Sig Leo Dean for the glycaemic improvement effect is higher, reduce the incidence of adverse reactions, so more medication safety, it is worthy of clinical promotion Application.
出处
《中国生化药物杂志》
CAS
2017年第8期252-253,256,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
格列齐特
西格列汀
胰岛素控制欠佳
肥胖2型糖尿病
疗效
gliclazide
Sig Leo Dean
poor glycemic control
obese type 2 diabetes mellitus
curative effect
